News & Events
Spot our Highlights & News
Opening of our new application labs & office in San Diego
2017 / 12 / 08
It’s official: last night we celebrated the opening of our San Diego office.
On December 7th, 2017 we welcomed invited guests to our new space for a good old-fashioned office warming party. Employees, customers & friends came together to celebrate the new location enjoying tasty food, good drinks & the joyous atmosphere.
Located in the Miramar neighbourhood of San Diego, CA, the new office is a bright airy space with lots of (technical) details to explore.
Stop by – we are very much looking forward to welcoming you at our new application labs & office space!
Dynamic Biosensors Inc.
San Diego, CA 92126, USA
Launch of switchSENSE® MP3 multi-purpose chip
with 3 nanolever densities. Ligand density control made easy.
2017 / 11 / 29
Trying to decipher complex binding interactions?
Ligand density control is the key.
Introducing the switchSENSE® multi-purpose chip MP3 with its three predefined ligand surface densities.
Makes it easy to experiment with different and ultra-low densities, and ensures quick experimental success even for challenging interactants.
- Ready-to-use biosensors prepared with 3 different nanolever (ligand) densities.
- Compatible with Invisibility Cloaking and Electrical Desorption for the user-controlled adjustment of ligand densities.
- Fluorescence-based switchSENSE® technology for reliable analyte binding detection.
Compatible with dynamic and static measurement modes.
- 2D surface attachment (no matrix effects).
- Sequences are compatible with standard switchSENSE® Multi-Purpose-Chips (MPC).
Scripps researchers utilize the versatility of Dynamic Biosensors’ smart molecular interaction technology for biophysical characterizations
2017 / 11 / 17
LA JOLLA, CA – As part of a six-month collaboration, Dynamic Biosensors Inc. installed in August 2017 one of their dual-color DRX2 analyzer instruments for molecular interaction analysis and biophysical characterization in Prof. Jeffery W. Kelly’s lab. Using the patented switchSENSE® technology, the DRX2 system provides smart solutions for binding kinetics measurements, the analysis of absolute protein sizes and aggregate formation, protein conformational changes and melting behavior, as well as bispecific antibody affinity and avidity properties. Over the course of the past two months, this collaboration has grown and to include 14 Scripps scientists – from six research groups across three different departments – who utilize the versatility of the technology for their diverse research topics.
Of the first to use the technology was senior postdoctoral research associate, Dr. Gareth Morgan, from the Kelly Group. Dr. Morgan used the switchSENSE® technology, particularly the unique protein sizing analysis, to assess the unfolding and refolding processes upon melting or urea denaturation of light chain, known to play a crucial role in neurodegenerative diseases. The determination of the absolute hydrodynamic diameter at distinct time intervals during the target protein’s unfolding process revealed novel insights into the refolding kinetics and structural properties of the target.
Prof. Kelly and Dr. Morgan say “when we try to understand complex biological systems, teasing apart individual processes is essential. If we try to measure protein misfolding in bulk solution, we often see a protein subpopulation that aggregates, which obscures the most interesting molecular changes when studying aggregation disease-associated proteins. The switchSENSE® technology allows us to look at protein molecules that are isolated from each other, so that we can be more certain of what we’re actually measuring employing individual proteins. What is really powerful is that these measurements provide information that has distinct attributes, relative to what we have been able to measure previously. For example, this approach enables us to ascertain how a protein changes its shape when it unfolds and refolds, which is an important factor in determining why some proteins adopt a misfolded subpopulation, leading to aggregation and pathology, while others do not. The robust and accessible surface chemistry of the DRX2 instrument meant that we could efficiently adapt our experiments to the switchSENSE® system. We are encouraged by the preliminary results, that should provide novel insights into the misfolding and aggregation processes contributing to neurodegenerative diseases.”
For the duration of this collaboration, scientists from Dynamic Biosensors will closely support Scripps researchers by training them to use the DRX2 system and enabling them to independently design and set up their diverse experiments.
If you are interested in using the DRX2 analyzer platform for your research, or if you would like further information on the switchSENSE® technology and its applicability to your project goals, please contact Kenneth Dickerson (email@example.com) or Assoc. Prof. Evan Powers (firstname.lastname@example.org), the DRX2 responsible at Scripps.
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world’s largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine—work toward their next discoveries. The institute’s graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs.
For more information, see www.scripps.edu
About Dynamic Biosensors
Dynamic Biosensors is a provider of instruments, consumables, and services in the field of analytical systems for the characterization of biomolecules and molecular interactions. The company commercializes switchSENSE® technology, a groundbreaking platform technology for the analysis of biomolecules with applications in R&D and drug development. The switchSENSE® technology is protected worldwide and only available through Dynamic Biosensors. The development of the technology has been partially funded by a GO-Bio project grant from the German Federal Ministry of Education and Research (BMBF). The company is headquartered in the south of Munich, Germany and runs offices in the United States, the United Kingdom, in France, Japan and Singapore.
For more information, see www.dynamic-biosensors.com
Marketing & Communications Manager
Tel: +49 (0)89 / 89 74 544 – 21
Translational Oncology Symposium
Moores Cancer Center
La Jolla, California / USA
Feb 22, 2018
Belgian & British Biophysical Societies
Palace of Academics
Feb 22 – 23, 2018
Biologics & Biosimilars Congress
Maritim proArte Hotel
March 5 – 6, 2018
switchSENSE® User Meeting
Conference venue tbd
June 6 – 8, 2018
switchSENSE® User Meeting
Conference venue tbd
San Diego, CA, USA
June 20 – 22, 2018
WE WILL GET IN TOUCH WITH YOU SHORTLY.
What are you interested in? *
Consumables & Reagents
Quotes & Orders
Instruments & Applications
Technical & Software Support
New to switchSENSE®
General Info & Evaluation